Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PROCTER & GAMBLE HEALTH - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PROCTER & GAMBLE HEALTH CADILA HEALTHCARE/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 29.3 59.3 49.4% View Chart
P/BV x 4.7 7.3 64.6% View Chart
Dividend Yield % 0.7 6.5 11.3%  

Financials

 CADILA HEALTHCARE   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
PROCTER & GAMBLE HEALTH
Dec-18
CADILA HEALTHCARE/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3523,549 9.9%   
Low Rs2071,301 15.9%   
Sales per share (Unadj.) Rs139.2511.4 27.2%  
Earnings per share (Unadj.) Rs11.861.3 19.2%  
Cash flow per share (Unadj.) Rs18.674.0 25.1%  
Dividends per share (Unadj.) Rs3.50440.00 0.8%  
Dividend yield (eoy) %1.318.1 6.9%  
Book value per share (Unadj.) Rs101.4927.8 10.9%  
Shares outstanding (eoy) m1,023.7416.60 6,167.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.04.7 42.3%   
Avg P/E ratio x23.739.6 60.0%  
P/CF ratio (eoy) x15.032.8 45.9%  
Price / Book Value ratio x2.82.6 105.5%  
Dividend payout %29.8717.9 4.1%   
Avg Mkt Cap Rs m286,03340,257 710.5%   
No. of employees `00013.41.1 1,182.1%   
Total wages/salary Rs m24,1451,313 1,839.3%   
Avg. sales/employee Rs Th10,632.77,486.7 142.0%   
Avg. wages/employee Rs Th1,801.21,157.6 155.6%   
Avg. net profit/employee Rs Th898.5897.2 100.1%   
INCOME DATA
Net Sales Rs m142,5318,490 1,678.8%  
Other income Rs m1,139244 467.0%   
Total revenues Rs m143,6708,734 1,645.0%   
Gross profit Rs m24,1981,482 1,633.2%  
Depreciation Rs m6,965211 3,297.8%   
Interest Rs m3,4180-   
Profit before tax Rs m14,9541,514 987.5%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m3,198563 568.5%   
Profit after tax Rs m12,0441,017 1,183.8%  
Gross profit margin %17.017.5 97.3%  
Effective tax rate %21.437.1 57.6%   
Net profit margin %8.512.0 70.5%  
BALANCE SHEET DATA
Current assets Rs m87,15415,343 568.0%   
Current liabilities Rs m82,6941,960 4,218.7%   
Net working cap to sales %3.1157.6 2.0%  
Current ratio x1.17.8 13.5%  
Inventory Days Days7149 146.6%  
Debtors Days Days9428 329.8%  
Net fixed assets Rs m133,2361,209 11,017.6%   
Share capital Rs m1,024166 616.9%   
"Free" reserves Rs m102,73315,235 674.3%   
Net worth Rs m103,75715,401 673.7%   
Long term debt Rs m32,1460-   
Total assets Rs m236,86617,595 1,346.2%  
Interest coverage x5.4NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.5 124.7%   
Return on assets %6.55.8 112.9%  
Return on equity %11.66.6 175.7%  
Return on capital %13.710.3 133.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,7521,636 3,223.9%   
Fx outflow Rs m14,5044,368 332.0%   
Net fx Rs m38,248-2,732 -1,400.1%   
CASH FLOW
From Operations Rs m25,054-1,304 -1,921.6%  
From Investments Rs m-10,12312,697 -79.7%  
From Financial Activity Rs m-10,942-301 3,641.3%  
Net Cashflow Rs m3,98911,093 36.0%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 8.3 18.2 45.6%  
FIIs % 5.9 1.0 590.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 29.1 37.8%  
Shareholders   44,069 28,591 154.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT  NOVARTIS  DR. DATSONS LABS  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 450 Points in Opening Trade; Mindtree Up 5% Post Q3 Results(09:30 am)

Asian share markets and US stock futures are trading higher today as investors awaited comments from Joe Biden's Treasury Secretary nominee Janet Yellen on US stimulus and the dollar.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 19, 2021 11:24 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - WYETH COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS